Answers are grounded in this paper and cite their sources.
TOPIC: This systematic review and meta-analysis evaluated the cumulative prevalence of ocular complications following implantation of Artisan®/Verisyse® iris-fixated phakic intraocular lenses in adult patients undergoing refractive surgery. Outcomes included postoperative ocular complications and longitudinal loss of endothelial cell density (ECD). CLINICAL RELEVANCE: Phakic intraocular lenses are widely used to correct moderate-to-high refractive errors. Available evidence on complication rates is heterogeneous and often limited to narrative reports, hindering accurate risk counseling and long-term clinical decision-making. METHODS: This study was conducted according to PRISMA guidelines and was registered in PROSPERO (CRD420251150677). Eligible studies included ≥10 eyes implanted with Artisan®/Verisyse® lenses reporting postoperative complications. Risk of bias was assessed using design-specific tools. Proportion meta-analyses were performed with subgroup analyses comparing real-world evidence studies versus clinical trials. ECD loss was analyzed from three months to 10 years post-implantation. Certainty of evidence was evaluated using GRADE. RESULTS: Fifty-five studies were included. Iris atrophy was the most common complication (20.3%, 95% CI: 5.7-52.1). Other complications included pupil ovalization (7.6%, 95% CI: 4.8-12.5), progressive reduction in visual acuity (7.6%, 95% CI: 5.8-9.5), position-related complications (including rotation, dislocation, subluxation, and luxation) (6.7%, 95% CI: 1.9-33.4), uveitis (6.2%, 95% CI: 4.3-9.1), and halos (5.3%, 95% CI: 3.2-7.9). Ocular hypertension (4.7%, 95% CI: 2.4-7.9), cataract (2.8%, 95% CI: 1.6-3.5), corneal decompensation (2.6%, 95% CI: 1.8-6.5), and retinal detachment (1.1%, 95% CI: 0.7-1.3) occurred less frequently. Subgroup analyses showed higher rates of corneal decompensation in real-world studies (4.2% vs. 1.3%; p = 0.04) and traumatic position-related complications (5.0% vs. 0.8%; p = 0.02), whereas ocular hypertension was more frequent in clinical trials (14.1% vs. 2.3%; p < 0.01). ECD loss increased from 5.3% at 3 months to 15.8% at 10 years. Certainty of evidence ranged from very low to moderate, with substantial heterogeneity across outcomes. CONCLUSION: Despite overall acceptable safety, Artisan®/Verisyse® implantation is associated with measurable ocular complications and progressive ECD loss.
No takes yet. Share an insight, caveat, or question.
Mejía‐Salgado et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: